|Bid||134.74 x 300|
|Ask||134.86 x 100|
|Day's Range||132.18 - 135.70|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-239.96|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.
Gilead Sciences, Inc.'s revenue is estimated to decline by just over 18% when it reports its Q2 results.
Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.